Domain Therapeutics
The company develops small molecule and antibody therapies that target G-protein coupled receptors (GPCRs) to modulate the immune system. Its clinical-stage pipeline focuses on treating solid tumors in immuno-oncology and various inflammatory conditions. Key assets include EP4 receptor antagonists, anti-CCR8 depleting antibodies, and PAR2 biased antagonists.
Biotechnology
Immuno-oncology
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €45.9M
- Funding rounds
- 2
Investors in Domain Therapeutics
Investors on record for Domain Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Domain Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors